After a series of delays for bad weather, the ill-health of an astronaut and then a wait for the splashdown of the previous mission this morning the world’s only re-usable orbital rocket take four astronauts to the International Space Station (ISS) as SpaceX and NASA launch the Crew-3 mission.
Originally due to launch on October 27 2021 from NASA’s Kennedy Space Center in Florida, NASA has now confirmed that its SpaceX Crew-3 mission will take-off no earlier than 9:03 p.m. EST on Wednesday, November 10 2021.
After the night launch the Falcon 9 rocket will attempt to land on a drone-ship in the Atlantic.
It will be SpaceX’s fourth NASA flight with astronauts, though last month it also successfully launched and landed the first all-civilian private astronaut crewed mission to orbit Earth.
Wastewater samples are being used to track the spread of SARS-CoV-2.
It’s sometimes called ‘wastewater-based epidemiology’ (WBE) – a scientific and public health field that involves detecting and monitoring specific molecules in untreated wastewater, to determine how prevalent they are. First proposed more than 70 years ago as a way to track the spread of the deadly poliovirus, WBE has since been used to measure human population exposure to pollutants, and even to estimate the level of drug consumption in major cities. In 2,020 it hit global news headlines when it was first proposed as a way to track SARS-CoV-2, the virus that causes COVID-19.
A team of scientists from the University of Florida (UF) will use a $1.1 million grant to further their work on the use of artificial intelligence-or AI-powered medical research for predicting and diagnosing Parkinson’s disease while maintaining patient privacy.
This grant, from the National Institutes for Health (NIH), will allow the scientists to train artificial neural network models — computer systems modeled on the human brain and nervous system — and further develop AI technologies that can predict and diagnose Parkinson’s, according to a press release.
“The proposed research will remove a major roadblock that restricts medical data accessibility and hinders cloud-based operations of deep-learning artificial neural networks for biomedical research,” the investigators said.
EVP, patient advocacy & engagement, national patient advocate foundation.
Gwen Darien is Executive Vice President for Patient Advocacy and Engagement, at the National Patient Advocate Foundation (https://www.npaf.org/), an organization with a mission of bringing patient voices to health system delivery reform, developing and driving initiatives promoting equitable access to affordable quality health care, and prioritizing the patient voice in health system delivery reform to achieve person-centered care. She is also Executive Vice President at their sister organization, Patient Advocate Foundation (https://www.patientadvocate.org/), a national non-profit organization which provides case management services and financial aid to Americans with chronic, life threatening and debilitating illnesses.
Gwen is a longtime patient advocate who has played leadership roles in some of the country’s preeminent nonprofit organizations.
As a three-time cancer survivor herself, Gwen came into cancer advocacy expressly to change the experiences and outcomes for the patients who came after her and to change the public dialogue about cancer and other life-threatening illnesses.
In 2,005 Gwen started the first stand-alone advocacy entity in a professional cancer research organization, at the American Association for Cancer Research, launching CR magazine – a magazine for people with cancer and those who care for them. Later, she served as the executive director of the Samuel Waxman Cancer Research Foundation; director of The Pathways Project; and executive vice president of programs and services at the Cancer Support Community, where in each role, Gwen championed placing patients at the center of health system change, whether it was for research, public policy or direct services.
While serving as the chair or on the board of a wide range of program committees and workshop faculties, including the Community Engagement in Genomics Working Group of the National Human Genome Research Institute; a member of the US Pharmacopeia Board of Trustees; and as the past chair of PCORI’s Patient Engagement Advisory Panel, Gwen also continues to write about her experiences. Her most recent piece, Transformation: My Experience as a Patient and an Advocate in Three Chapters appeared in the National Academy of Medicine Perspectives (https://nam.edu/transformation-my-experience-as-a-patient-and-an-advocate-in-three-chapters/).
Displacing Delta. Expect this to dominate globally in the coming year, if truly 10% more transmissible.
An offshoot of the Delta coronavirus variant which is slowly spreading throughout the UK is expected to be dominant within a matter of months, experts believe.
Known as AY.4.2, the sub-variant is thought to be at least 10 cent more transmissible than its predecessor, with analysis underway to determine what accounts for its increased infectiousness.
The UK Health Security Agency (UKHSA) has said that early tests do not suggest that AY.4.2, which has been labelled a ‘Variant Under Investigation’, has acquired the ability to evade immunity generated by infection or injection.
“De-Extinction” Biotechnology & Conservation Biology — Ben Novak, Lead Scientist Revive & Restore
Ben Novak is Lead Scientist, at Revive & Restore (https://reviverestore.org/), a California-based non-profit that works to bring biotechnology to conservation biology with the mission to enhance biodiversity through the genetic rescue of endangered and extinct animals (https://reviverestore.org/what-we-do/ted-talk/).
Ben collaboratively pioneers new tools for genetic rescue and de-extinction, helps shape the genetic rescue efforts of Revive & Restore, and leads its flagship project, The Great Passenger Pigeon Comeback, working with collaborators and partners to restore the ecology of the Passenger Pigeon to the eastern North American forests. Ben uses his training in ecology and ancient-DNA lab work to contribute, hands-on, to the sequencing of the extinct Passenger Pigeon genome and to study important aspects of its natural history (https://www.youtube.com/watch?v=pK2UlLsHkus&t=1s).
Ben’s mission in leading the Great Passenger Pigeon Comeback is to set the standard for de-extinction protocols and considerations in the lab and field. His 2018 review article, “De-extinction,” in the journal Genes, helped to define this new term. More recently, his treatment, “Building Ethical De-Extinction Programs—Considerations of Animal Welfare in Genetic Rescue” was published in December 2019 in The Routledge Handbook of Animal Ethics: 1st Edition.
Ben’s work at Revive & Restore also includes extensive education and outreach, the co-convening of seminal workshops, and helping to develop the Avian and Black-footed Ferret Genetic Rescue programs included in the Revive & Restore Catalyst Science Fund.
Ben graduated from Montana State University studying Ecology and Evolution. He later trained in Paleogenomics at the McMaster University Ancient DNA Centre in Ontario. This is where he began his study of passenger pigeon DNA, which then contributed to his Master’s thesis in Ecology and Evolutionary Biology at the University of California Santa Cruz. This work also formed the foundational science for de-extinction.
Ben also worked at the Australian Animal Health Laboratory–CSIRO (Commonwealth Scientific and Industrial Research Organisation) to advance genetic engineering protocols for the pigeon.
The COVID-19 pandemic, caused by SARS-CoV-2, continues to rage in many countries, straining health systems and economies. Vaccines protect against severe disease and death and are considered central to ending the pandemic. COVID-19 vaccines (and SARS-CoV-2 infection) elicit antibodies that are directed against the viral spike (S) protein and neutralize the virus. However, the emergence of SARS-CoV-2 variants with S protein mutations that confer resistance to neutralization might compromise vaccine efficacy[1]. Furthermore, emerging viral variants with enhanced transmissibility, likely due to altered virus-host cell interactions, might rapidly spread globally. Therefore, it is important to investigate whether emerging SARS-CoV-2 variants exhibit altered host cell interactions and resistance against antibody-mediated neutralization.
The non-E5 made rats healthier with a small increase in lifespan. The E5 part 2 is still ongoing with rats at 31 months that generally at most live 36 months.
In this video we give a brief update on the parallel experiments being conducted by Dr Katcher and Professor Goya. In these studies they are injecting E5 and young blood plasma into rats in repeatedly to see if the maximum lifespan can be extended.
The newsletter is here. https://www.ntzplural.com/newsletter.
Papers mentioned in this video. The original paper on BioXriv. Reversing age: dual species measurement of epigenetic age with a single clock. https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1 ******************************************** Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.
Disclosure: Some of the links provided are affiliate links. Although we may receive a small commission from the affiliate, the cost of the product for you will always be the same, or often discounted. Thank you for supporting our channel.
******************************************* Alive By Science — All products 10% Embedded Discount Code Link — https://tinyurl.com/w8mk2zc. Direct link to Liposomal Glutathione. https://tinyurl.com/emypha8y.
Alive By Science NAD test 10% discount. https://tinyurl.com/4umms2nz.
~ New ~ Our Bone Health Supplement: https://iherb.co/wJ14LbC BioGaia, Osfortis with Vitamin D, 60 Capsules. iHerb New Customer 5% off.
Dr. Ann Marie Kimball (https://epi.washington.edu/faculty/kimball-ann-marie/) is a physician, epidemiologist and currently holds the roles of Associate Fellow at the international affairs think tank Chatham House, and Vice Chair, COVID 19 task force, at The Rotary Foundation / Rotary International.
Previously, Dr. Kimball served as a strategic advisor to the Rockefeller Foundation, supporting the strengthening and development of strategies for Ebola, post-Ebola, and health crisis response, including planning and guiding the formation of a regional disease surveillance network in collaboration with Connecting Organizations for Regional Disease Surveillance (CORDS).
Before joining the Rockefeller Foundation, Dr. Kimball served as technical and strategic lead for the Bill and Melinda Gates Foundation surveillance strategy formation.
Prior to Gates, Dr. Kimball served as Professor of Epidemiology for the University of Washington (UW), School of Public Health, with adjunct appointments in Medicine (Bioinformatics and Infectious Diseases) and the Jackson School of Foreign Affairs. During her tenure at UW, Dr. Kimball founded and directed the APEC Emerging Infections Network, and led research and training programs in Surveillance and Informatics in Peru and Thailand.
Dr. Kimball’s research focus on global trade and emerging infections earned her a Fulbright New Century Scholars award and a Guggenheim Scholars award.
Dr. Kimball is also the author of Risky Trade: Infectious Diseases in an Era of Global Trade, which was highly reviewed by NEJM, Emerging Infections and Lancet. She has authored numerous scientific publications, and served on numerous Institute of Medicine panels. She is also a fellow in the American College of Preventive Medicine and member of the National Biosurveillance Advisory group (NBAS) from the Centers for Disease Control.
Balancing Risk and Cutting Edge Medical Innovation — Dr. Paul Offit, MD, Director, Vaccine Education Center, Children’s Hospital of Philadelphia.
Dr. Paul A. Offit, MD, (https://www.paul-offit.com/) is an internationally recognized expert in the fields of virology and immunology, Co-Inventor of a landmark vaccine for the prevention of Rotavirus gastroenteritis, and holds multiple titles including — Director of the Vaccine Education Center at Children’s Hospital Of Philadelphia (CHOP), Maurice R. Hilleman Chair of Vaccinology and Professor of Pediatrics, Perelmann School of Medicine, University of Pennsylvania, and Adjunct Associate Professor, The Wistar Institute of Anatomy and Biology.
Dr. Offit was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention, a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine, and co-editor of the foremost vaccine text, Vaccines.
Dr. Offit is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal.
Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of a landmark rotavirus vaccine recommended for universal use in infants by the CDC.
For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation’s Living Proof Project for global health. In addition, he has received numerous other awards and honors for his groundbreaking work.
Dr. Offit is also an author of many books including, but not limited to: Vaccinated: One Man’s Quest to Defeat the World’s Deadliest Diseases, Overkill: When Modern Medicine Goes Too Far, The Cutter Incident: How America’s First Polio Vaccine Led to the Growing Vaccine Crisis, Breaking the Antibiotic Habit, Do You Believe in Magic, and his most recent, You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation.
